Hikma Highlights Long-Term Importance Of Biosimilars
CEO Siggi Olafsson Discusses The Evolution Of Hikma’s Injectables Business
Playing in biosimilars is essential for firms that want to lead in the sterile injectables space, Hikma CEO Siggi Olafsson commented as he discussed how the firm’s injectables business was expected to evolve over the coming years.
You may also be interested in...
After a wave of big pharma interest in the biosimilars arena, originator enthusiasm for the sector appears to be waning – potentially opening up an opportunity for newcomers to compete on off-patent biologics.
Following a challenging first half for Hikma, executive chairman and CEO Said Darwazah talks to Generics Bulletin about how the firm is planning to be more active in making deals happen, as well as how it plans to address pressures on its Generics division that led to two consecutive downgrades in guidance this year.
Hikma has added yet another Celltrion biosimilar to its marketing partnership in the Middle East and North Africa region, in the form of the Korean company’s Yuflyma higher-strength adalimumab rival to Humira.